Endocare launches cryoablation system in China:
This article was originally published in Clinica
Endocare has launched its CRYOcare system for the treatment of metastatic liver cancer in China. The Irvine, California-based company has already set up a training centre and sold systems to select surgical centres. It has also formed a distribution agreement with Charlson International, which is based in Hong Kong. Endocare says the Chinese market is attractive because the incidence of liver cancer is extremely high compared with Western countries because of the proliferation of the hepatitis virus. Around 10% of the more than 100 million chronic carriers of the Hepatitis B virus are expected to develop primary liver cancers, says Endocare.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.